Compare Dominion Energy Inc (D) vs Moderna, Inc. (MRNA) Price & Performance

Dominion Energy (D) trades at $61.69, up 0.25% with a bearish technical signal despite recent earnings beats. The company shows strong fundamental improvement with revenue growing to $16.51B in 2025 and net income margin expanding to 18.16%. Analyst consensus is mixed with 36% buy ratings but a $71.56 price target suggests 16% upside potential. Recent news highlights the pending merger with NextEra Energy and ongoing infrastructure investments.

Dominion Energy presents a compelling value opportunity with reasonable valuation multiples (P/E 21.37, P/S 2.96) and consistent earnings outperformance. However, the stock faces headwinds from high debt levels (debt-to-asset ratio 43.49%) and regulatory uncertainty surrounding the proposed merger. The dividend yield of approximately 4.3% provides income support while investors await merger resolution and continued operational execution.

Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.

Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.